SPRC Live signals | Maximize Profits with Getagraph.com

SELL 143402 min ago

@ $3.99

Issued: 6 Feb 2024 @ 09:45

Return: -69.92%

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 16:00):

Stats
Today's Volume	109 499
Average Volume	850 554
Market Cap	2.94M
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00700 (0.58%)

Volume Correlation

Long: -0.02 (neutral)

Short: -0.39 (neutral)

Signal:(37.83) Neutral

SciSparc Ltd. Correlation

10 Most Positive Correlations
MXIM	0.937
ORPH	0.935
RGF	0.93
RETO	0.929
APTO	0.924
QLGN	0.923
NDLS	0.922
PRTS	0.92
CFRX	0.919
BIVI	0.917

10 Most Negative Correlations
ACQR	-0.942
MLAI	-0.94
KAII	-0.94
TBSA	-0.939
MCAA	-0.938
NVSA	-0.937
FTAA	-0.936
AHRN	-0.936
FRSG	-0.935
SCOB	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SciSparc Ltd. Correlation - Currency/Commodity

-0.75
( moderate negative )

-0.71
( moderate negative )

0.00
( neutral )

0.31
( neutral )

SciSparc Ltd. Financials

Annual	2023
Revenue:	$2.88M
Gross Profit:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2023
Revenue:	$2.88M
Gross Profit:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2022
Revenue:	$1.35M
Gross Profit:	$1.03M (76.10 %)
EPS:	$-14.73

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

SciSparc Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.